Literature DB >> 21496568

Huntington's disease - clinical signs, symptoms, presymptomatic diagnosis, and diagnosis.

Kathleen M Shannon1.   

Abstract

HD is a complex illness, with a broad clinical picture that begins years before clear motor onset and evolves over decades to a terminal state of extreme disability. It challenges the resources of families and communities and the skills of medical and ancillary health care providers. A broader understanding of the phenotypes, progression, and genetic basis of HD may elevate the standard of care for these deserving patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21496568     DOI: 10.1016/B978-0-444-52014-2.00001-X

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  11 in total

Review 1.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

2.  Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin.

Authors:  Scott D Olson; Amal Kambal; Kari Pollock; Gaela-Marie Mitchell; Heather Stewart; Stefanos Kalomoiris; Whitney Cary; Catherine Nacey; Karen Pepper; Jan A Nolta
Journal:  Mol Cell Neurosci       Date:  2011-12-08       Impact factor: 4.314

Review 3.  Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis.

Authors:  Sylvette Ayala-Peña
Journal:  Free Radic Biol Med       Date:  2013-04-18       Impact factor: 7.376

4.  A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease.

Authors:  Daniel Todd; Ian Gowers; Simon J Dowler; Michael D Wall; George McAllister; David F Fischer; Sipke Dijkstra; Silvina A Fratantoni; Rhea van de Bospoort; Jessica Veenman-Koepke; Geraldine Flynn; Jamshid Arjomand; Celia Dominguez; Ignacio Munoz-Sanjuan; John Wityak; Jonathan A Bard
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

Review 5.  Risk-taking and pathological gambling behavior in Huntington's disease.

Authors:  Carla Kalkhoven; Cor Sennef; Ard Peeters; Ruud van den Bos
Journal:  Front Behav Neurosci       Date:  2014-04-02       Impact factor: 3.558

6.  The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease.

Authors:  Alba Di Pardo; Elena Ciaglia; Monica Cattaneo; Anna Maciag; Francesco Montella; Valentina Lopardo; Anna Ferrario; Francesco Villa; Michele Madonna; Enrico Amico; Albino Carrizzo; Antonio Damato; Giuseppe Pepe; Federico Marracino; Alberto Auricchio; Carmine Vecchione; Vittorio Maglione; Annibale A Puca
Journal:  Cell Death Dis       Date:  2020-07-18       Impact factor: 8.469

Review 7.  The Role of NADPH Oxidases and Oxidative Stress in Neurodegenerative Disorders.

Authors:  Anuradha Tarafdar; Giordano Pula
Journal:  Int J Mol Sci       Date:  2018-11-30       Impact factor: 5.923

8.  The Role of Microglia and Astrocytes in Huntington's Disease.

Authors:  Thulani H Palpagama; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  Front Mol Neurosci       Date:  2019-10-25       Impact factor: 5.639

9.  Examination of Huntington's disease in a Chinese family.

Authors:  Mingxia Yu; Xiaogai Li; Sanyun Wu; Ji Shen; Jiancheng Tu
Journal:  Neural Regen Res       Date:  2014-02-15       Impact factor: 5.135

10.  The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington's disease model.

Authors:  Matthew B Veldman; Yesenia Rios-Galdamez; Xiao-Hong Lu; Xiaofeng Gu; Wei Qin; Song Li; X William Yang; Shuo Lin
Journal:  Mol Neurodegener       Date:  2015-12-09       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.